National Cancer Institute Awards Small Business Innovation Research Contract to Rules-Based Medicine, Inc.
Posted on: Thursday, 18 December 2008, 06:00 CST
RBM, located in
"An early diagnostic screen for ovarian cancer could greatly increase the
chances of survival," said
"Our search for additional biomarkers -- and combinations of
biomarkers -- for early disease detection is an ongoing effort," said
Under the two phases of this project, RBM will develop and test quantitative, multiplexed immunoassays incorporating 19 additional analytes the two companies have identified as promising targets potentially capable of enhancing accuracy of ovarian cancer detection. Correlogic will expand its existing analytic platform to determine the efficacy of incorporating these additional analytes into the existing assay. Upon completion RBM will add the 19 assays to its automated RBM Human Multi-Analyte Profile platform, HumanMAP(R).
The project is being funded in whole or in part with Federal funds from the NCI, the National Institutes of Health, and the Department of Health and Human Services under Contract No. HHSN261200800045C. RBM received two "fast-track" SBIR awards in 2007.
About Ovarian Cancer
The American Cancer Society estimates ovarian cancer will strike 21,650 women and take the lives of 15,520 women in 2008. It is the most deadly gynecologic cancer, accounting for more than 55 percent of all gynecologic cancer deaths. But ovarian cancer is also among the most treatable if it is caught early. When ovarian cancer is diagnosed early and appropriately treated, 5-year survival is 93 percent. However, less than 20 percent of all ovarian cancers are found in this early stage. Progress continues, with the development of new tests to aid in diagnosis of certain symptomatic women. With further enhanced sensitivity and specificity that additional research may provide, tests can be appropriate for a wider population of women.
About Rules-Based Medicine
Rules-Based Medicine (RBM) provides comprehensive protein biomarker products and services centered on its Multi-Analyte Profiling (MAP) technology. Its service platform (RodentMAP(R) and HumanMAP(R)) provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins cost-effectively in multiple species, and from a small sample volume. The Company also offers innovative and proprietary ex vivo testing systems such as TruCulture(TM), the first fully-closed, reproducible whole blood culture system. RBM is actively developing multiplex diagnostic tests to detect the presence of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. More information about RBM is located at http://www.rbmmaps.com.
About Correlogic Systems
Correlogic Systems, Inc. has developed patented technology and processes
with a wide variety of applications for biomarker discovery, disease
detection, and new drug discovery. The technology's first application has been
in the field of proteomics - the study of human proteins. OvaCheck(R), a blood
test for detection of ovarian cancer, is Correlogic's first diagnostic test
using its patented "Hidden Patterns" approach. Correlogic has entered into
marketing agreements with Quest Diagnostics, Inc., and Laboratory Corporation
of America for OvaCheck in
Cautionary Statement: Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results could differ materially due to, among other things, operational and other difficulties associated with integrating acquired business, general business conditions, competition among managed care companies, rising health costs, trends in medical loss ratios, health care reform, delay in receipt of regulatory and other approvals for pending transactions and other regulatory issues.
RodentMAP(R) and HumanMAP(R) are registered trademarks of Rules-Based Medicine, Inc. OvaCheck(R) is a registered trademark of Correlogic Systems, Inc.
SOURCE Rules-Based Medicine, Inc.
Source: PR Newswire
Related Articles
- Perimeter Institute Faculty Member Jaume Gomis Wins Early Researcher Award
- ASSET is First to Support Intel's New Nehalem Micro-Architecture and Tolapai SOC With CPU Emulation Test and Diagnostics
- Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds
- Simple Blood Test Detects Breast Cancer Early
- New Study Shows InSure(R) Colorectal Cancer Screening Test Significantly Better at Detecting Early Stage Colorectal Cancers Compared to Traditional Test
- Dendritic Nanotechnologies Receives National Cancer Institute Contract to Develop Dendrimer-Based Diagnostic and Therapeutic Delivery System for Ovarian Cancer
- Mindreef Extends Leadership in SOA Testing and Diagnostics With Enhanced New Version of Mindreef SOAPscope; Powerful New Features Provide Advanced Testing, Diagnostics and Analysis
- BioCurex Blood Test Detects Very Early Stages of Breast Cancer With High Specificity
- Journal of the American Medical Association Reports Matritech's NMP22 BladderChek Test Detects Bladder Cancers Missed By Cystoscopy
- Test May Aid Early Detection of Alzheimers
 |
 |
User Comments (0)
RSS Feeds